Isotoxic Dose Escalation and Acceleration in Lung Cancer ChemoRadiotherapy
A
phase I/II trial of concurrent chemoradiation with
dose-escalated
radiotherapy
in patients with stage II or stage III
Non-Small
Cell Lung Cancer
Trial
objectives:
To investigate the toxicity,
feasibility and potential clinical effectiveness of dose-escalated RT with
concurrent chemotherapy in stage IIb or stage III
NSCLC as a potential experimental arm in future phase III trials. It will also allow the assessment and validation
of radiobiological models for predicting tumour control and normal tissue
complications.
Chief
Investigator: Dr David
Landau
Consultant
Clinical Oncologist Guy’s &
Email: david.landau @ kcl.ac.uk
Tel: 020 7188 3761
Fax: 020 7188 3751
Trial
co-ordinator: Kulsam
Ali
Cancer Research UK & UCL Cancer Trials Centre
Email: k.ali @ ctc.ucl.ac.uk
Tel: 020 7679 9284
Fax: 020 7679 9871
(Contact details to access Trial
protocol and Radiotherapy Planning and Delivery Guidelines)
QA contact: Elizabeth
Miles
National
Trials QA Team
Email: elizabeth.miles
@ nhs.net
Tel: 01923 844714
Fax: 01923
844138
( NB to use email addresses please remove space
before and after @ )
QA PROGRAMME
Pre-trial QA
requirements:
Questionnaires
- National radiotherapy trials QA Baseline questionnaire
- National radiotherapy trials QA staff questionnaire
Outlining
exercise
Patients A and C must be delineated according to the trial radiotherapy planning
and delivery guidelines and returned electronically to the RTTQA centre for
analysis.
- Patient
C PET
Planning
exercise
Patients D and E must be planned according to the trial radiotherapy
planning and delivery guidelines and returned electronically to the RTTQA
centre for analysis.
- Patient
E Planning CT
- Planning
spreadsheet
Ongoing QA
requirements:
Plan export
for all trial patients
Site visit